January 2018 | Targeted Therapies in Oncology

Taking on the Hospital/Community Practice Cost Differential

January 24, 2018

Clinical Articles

Just as CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, results from a new study show that cancer treatment costs remain significantly lower at community oncology clinics compared with hospitals.

Second-Line Chemotherapy Doublet Proves Noninferior to FOLFIRI in mCRC

January 12, 2018

Clinical Articles

According to the results of the randomized phase III AXEPT clinical trial, a chemotherapy doublet has proved noninferior to treatment with standard FOLFIRI (folinic acid [leucovorin], fluorouracil [5-FU], and irinotecan) for patients with previously treated metastatic colorectal cancer (mCRC).1